Imugene (ASX:IMU) Deferred Tax : A$0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

What is Imugene Deferred Tax?

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Imugene's change in deferred tax for the six months ended in Dec. 2023 was A$0.00 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00 Mil.

Imugene Deferred Tax Historical Data

The historical data trend for Imugene's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imugene Deferred Tax Chart

Imugene Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Deferred Tax

Get a 7-Day Free Trial

Imugene Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Deferred Tax	Get a 7-Day Free Trial															-	-	-	-	-

Imugene Deferred Tax Calculation

Deferred Tax for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

Imugene Deferred Tax Related Terms

Thank you for viewing the detailed overview of Imugene's Deferred Tax provided by GuruFocus.com. Please click on the following links to see related term pages.

Imugene (ASX:IMU) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imugene Ltd (ASX:IMU) » Definitions » Deferred Tax

Comparable Companies

Traded in Other Exchanges

IUGNF:USA

Address

4-6 Bligh Street, Suite 12.01, Level 12, Sydney, NSW, AUS, 2000

Website

https://www.imugene.com

Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its product includes HER-Vaxx,PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment being the Research and Development of oncolytic immunotherapies.

Imugene (ASX:IMU) Headlines

No Headlines